ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

RMJ. 2023; 48(1): 179-184


Total Neuropathy Scale Pediatric Vincristine to detect vincristine induced peripheral neuropathy in children with Acute Lymphoblastic Leukemia

Prastiya Indra Gunawan, Kartika Hardiyani, I Dewa Gede Ugrasena.



Abstract
Download PDF Post

Objective: To analyze the Total Neuropathy Scale Pediatric Vincristine (TNS-PV) score as a vincristine induced peripheral neuropathy (VIPN) diagnostic tool.
Methodology: This observational analytic study was conducted in Outpatient Pediatric Hematology Oncology Dr. Soetomo Hospital. The inclusion criteria were Acute Lymphoblastic Leukemia (ALL) children aged 4-18 years that had undergone chemotherapy treatment, received a cumulative dose of vincristine >12 mg/m2, had no muscle weakness and signed informed consent. The TNS-PV instrument were used to assess VIPN and nerve conduction studies (NCS) was used as the gold standard.
Results: A total of 54 children were enrolled, two refused to sign the informed consent. About 60% were male children, 76.9% aged

Key words: Acute Lymphoblastic Leukemia, total neuropathy scale pediatric visncristine, vincristine induced peripheral neuropathy.







Bibliomed Article Statistics

54
22
31
36
25
39
37
43
35
28
26
9
R
E
A
D
S

69

39

17

16

15

21

20

36

27

36

26

3
D
O
W
N
L
O
A
D
S
070809101112010203040506
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.